Avalon GloboCare (NASDAQ:ALBT) Stock Price Down 7.2% – What’s Next?

Shares of Avalon GloboCare Corp. (NASDAQ:ALBT) traded down 7.2% on Tuesday . The stock traded as low as $0.4850 and last traded at $0.5013. 179,305 shares were traded during mid-day trading, a decline of 12% from the average session volume of 202,606 shares. The stock had previously closed at $0.54.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Avalon GloboCare in a report on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Avalon GloboCare Trading Down 7.2%

The firm has a market capitalization of $2.13 million, a P/E ratio of -0.14 and a beta of -0.06. The business’s fifty day moving average is $0.97 and its 200 day moving average is $1.68.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.